Blackstone President Jon Gray Steers Capital Toward AI Cancer Research

Blackstone president Jon Gray and his wife, Mindy Gray, are directing more and more money into AI-driven cancer research, both through Blackstone's own investments and through their personal science philanthropy, Bloomberg reports.

What we know about the Grays' bet

According to Bloomberg, Jon Gray, who leads Blackstone Inc., the world's largest alternative asset manager with more than a trillion dollars in assets under management, has steadily increased the share of AI investments in the firm's portfolio. He and his wife, Mindy Gray, are applying the same principle to their personal science philanthropy, where they are also betting on AI in biomedical research aimed at fighting cancer.

• Jon Gray — president of Blackstone Inc., the world's largest alternative asset manager
• Where the money goes — Blackstone investments and the Gray family's personal science philanthropy
• Philanthropic focus — applying AI to research on cancer prevention and treatment

Why AI is becoming a tool in oncology

AI is seeing growing use in biomedicine. Models can analyze huge volumes of genomic and clinical data, predict protein structure and behavior, speed up the search for new drug candidate molecules, and spot patterns in diagnostic images that are hard for the human eye to catch. Philanthropy that combines AI with cancer research typically targets exactly these problems — faster therapy development and more accurate early diagnosis — rather than simply funding traditional lab grants.

The interest of major investors like the Grays in this pairing reflects a broader trend among asset managers and their families. Money from large funds and from their executives personally is increasingly flowing not only into AI infrastructure — data centers, chips, cloud computing — but also into applied AI work in medicine and basic science. This kind of philanthropy often serves as a proving ground: promising AI approaches that deliver results in nonprofit research projects later attract commercial venture funding.

Blackstone is already known for big bets on the physical infrastructure behind AI. In 2021, the firm acquired data center operator QTS Realty Trust, and it has since kept expanding its investments in data centers and the power capacity needed to run them. Carrying a similar logic — looking for growth where AI is reshaping an entire industry — into the Gray family's personal philanthropy looks like an extension of the same investment philosophy, applied to science and medicine rather than real estate and infrastructure.

This kind of philanthropy usually works differently from venture investing. It funds earlier-stage, riskier scientific ideas that aren't yet ready to attract conventional startup capital but that, if they pan out, can shape the direction of an entire field of medicine for decades — from early diagnosis to personalized therapy tailored to an individual patient's genome.

What it means

When the heads of the largest investment firms carry the logic of AI investing from business into personal philanthropy, it's another sign that big capital sees AI in medical research not as an experiment but as a promising, high-priority direction for years to come.